Roth Capital analyst Debjit Chattopadhyay reiterated a Buy rating on Nektar Therapeutics (NASDAQ:NKTR) with a$21 price target, following the news that NKTR’s partner Baxter International …
In a research report issued today, Roth Capital analyst Debjit Chattopadhyay maintained a Buy rating on Nektar Therapeutics (NASDAQ:NKTR) with a $21 price …
In a research report sent to investors today, Roth Capital analyst Debjit Chattopadhyay maintained a Buy rating on Nektar Therapeutics (NASDAQ:NKTR) with a …
In a research report released today, Brean Capital analyst Jonathan Aschoff maintained a Buy rating on Nektar Therapeutics (NASDAQ:NKTR) with a price target …
In a research report released today, analyst Debjit Chattopadhyay of Roth Capital maintained a Buy rating on Nektar Therapeutics (NASDAQ:NKTR) with a $21 price target, which …
In a research report issued today, Roth Capital analyst Debjit Chattopadhyay reiterated a Buy rating on Nektar Therapeutics (NASDAQ:NKTR) with a $21 price …
In a research report issued today, Roth Capital analyst Debjit Chattopadhyay maintained a Buy rating on Nektar Therapeutics (NASDAQ:NKTR) with a price target …
In a research report issued Tuesday, William Blair analyst John Sonnier assigned an Outperform rating on Nektar Therapeutics (NASDAQ:NKTR), following the approval of NKTR’s …
In a research report released today, Brean Capital analyst Jonathan Aschoff reiterated a Buy rating on Nektar Therapeutics (NASDAQ:NKTR) and raised his price target to …
